3545 results for «211»

Filter By

3545 results

Breakthrough studies: Key abstracts on PCI, TAVI and mitral valve repair

04 Oct 2024 – From AICT-AsiaPCR 2024

Discover the cutting-edge research and innovative solutions presented in the 'Best Abstracts of AICT-AsiaPCR 2024' session. This curated selection showcases the latest advancements in interventional cardiology, from groundbreaking comparisons of transcatheter mitral valve repair techniques to the impact of cerebral embolic protection devices in TAVI procedures....

Breakthrough studies: Key abstracts on PCI, TAVI and mitral valve repair

Managing severe calcified LAD lesions in STEMI: Insights from three cases

04 Oct 2024 – From AICT-AsiaPCR 2024

Dive into this compelling presentation highlighting three challenging STEMI cases involving severe proximal LAD calcified stenosis. Witness the ingenuity of interventional strategies as the presenter explores how drug-coated balloons can be a viable alternative to stents in acute MI management. Don't miss this opportunity to deepen...

Managing severe calcified LAD lesions in STEMI: Insights from three cases

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Daniele Giacoppo

Author

Daniele Giacoppo
INFINITY-SWEDEHEART

BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.

04 Mar 2024

Didn’t find what you were looking for?